Journals / Türk Hematoloji Onkoloji Dergisi / 2005 / Cilt: 15 - Sayı: 1

Quantitative analysis of t(8,21) and inv (16) via RT-PCR in patients with acute myeloid leukemia

Akut myeloid lösemili hastalarımızda t(8;21) ve inv (16)'nın kantitatif RT-PCR ile araştırılması

Pages
15–17
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, we aim to search t(8;21) and inv (16) abnormalities in AML cases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:It has been showed that there is a relation between chromosomal abnormality and prognosis in acute myeloid leukemia (AML).
📊
Key Findings & Data:There are many chromosomal abnormalities in AML patients and it is known that t(8;21) and inv(16) are good prognostic abnormalities.
💡
Conclusion & Impact:In this study, we aim to search t(8;21) and inv (16) abnormalities in AML cases.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

It has been showed that there is a relation between chromosomal abnormality and prognosis in acute myeloid leukemia (AML). There are many chromosomal abnormalities in AML patients and it is known that t(8;21) and inv(16) are good prognostic abnormalities. Recently the treatment has been planned according to these abnormalities. We investigated t(8,21) and inv(16) abnormalities by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) in 19 patients with AML. Morever conventional cytogenetic method was applied for all patients. Of whom 9 were men and 10 women. Age of avarage was 19 to 58 years. FAB morphologic classification follows as; 5 AML-Ml, 8 AML-M2, 5 AML-M4, 1 AML-M5. Complete remission was obtained in eighteen patients with first induction regimen, whereas in one patient after second induction. t(8;21) has been found in 1 patient with cytogenetic method and confirmed with RT-PCR. In this study, we aim to search t(8;21) and inv (16) abnormalities in AML cases.

Özet

Akut myeloid lösemilerde (AML) kromozomal anomaliteler ile prognoz arasında ilişki olduğu gösterilmiştir. Çok sayıda farklı kromozomal anomaliteler arasında t(8;21) ve inv(16)'nın varlığının iyi prognoz göstergesi olduğu kabul edilmektedir. Diğer kromozomal anomaliteler ise kötü prognostik değer olarak kabul edilmekte ve tedavi planı bunlara göre düzenlenmektedir. Biz de bu amaçla kliniğimizde tanı konulan 19 AML hastasında kantitatif reverz transkripsiyon polimeraz zincir reaksiyonu (RT-PCR) metoduyla t(8;21) ve inv(16) anormalliklerini inceledik. Ayrıca tüm hastalara klasik sitogenetik inceleme yapıldı. Hastaların 9'u erkek,10'u bayandı. Yaş aralığı 19-58’idi. Morfolojik olarak 5'i AML-M1, 8'i AML-M2, 5'i AML-M4, 1'i AML-M5 tipinde idi. Hastaların biri 2.indüksiyonda olmak üzere tüm hastalar ilk indüksiyon tedavisiyle remisyona girdi. Sitogenetik incelemede bir hastada t(8;21) saptandı ve RTPCR metoduyla t(8;21) teyid edildi. Diğer hastalarda yapısal ve sayısal olarak herhangi bir kromozomal düzensizliğe rastlanmadı.

🔖

Cite This Article

KALKANLI, S., IŞIKDOĞAN, A., SÖKER, M., MÜFTÜOĞLU, E., BATUN, S., YURT, M., AYYILDIZ, O. (2022). Quantitative analysis of t(8,21) and inv (16) via RT-PCR in patients with acute myeloid leukemia. Türk Hematoloji Onkoloji Dergisi, Cilt: 15 - Sayı: 1, 15–17. https://ajindex.com/articles/624739

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Berger R, Bernheim A, Ochva-Noguera ME, etal. Prognostic significance of chromosomal abnormalities inacute nonlymphocytic leukemia. A study of 343 patients. Cancer Genet Cytogenet 28:293-299, 1987
  2. Cortes JE, Kantarjian H,O'Brien S, et al. Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. Leukemia 9:115-117, 1995
  3. Arthur DC, Berger R, Golomb HM, et al. The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet 40:203-216, 1989
  4. Poirel H, Radford-Weiss I, Rack K, et al. Detection of chromosome 16 CBF beta-MYHll fusion transcript in myelomonocytic leukemias.Blood 85: 1313-1322, 1995
  5. Marcucci G, Livak KJ,Bi W, etal. Detection of minimal residual disease in patients with AMLl/ETO-associated acute myeloid leukemia using novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 12:1482-1489, 1998
  6. Pedersen-Bjergaard J, Philip P, Larsen SO, et al. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 76:1083-1091,1990
  7. Sievers EL, Loken MR. Detection of minimal residuel disease in acute myelogenous leukemia. J Pediatr Hematol Oncol 17:123-133, 1995
  8. Miyamoto T, Nagafuji K, Harada M, et al. Quantitative analysis of AML 1 /ETO transcripts in peripheral blood stem cell harvest from patients with t(8;21) acute myelogenous leukemia. Br J Haematol 91:132-138, 1995
  9. Laczika K, Novak M, Hilgarth B, et al. Competitive CBFbeta/MYHl 1 reverse-transcriptase polymerase chain reaction for quantitative assesment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study. J Clin Oncol 16:1519-1525, 1998
  10. Schlenk RF, Benner A, Hartmann F, et al. Riskadapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.Leukemia 17(8):1521-1528,2003.